An Osaka University-led research team has recently published findings that provide a ray of hope for the millions of Parkinson’s disease (PD) sufferers worldwide. Although more common in those aged over sixty, PD can strike at any age, with an estimated prevalence of 41 per 100,000 people in their forties. And while not fatal in and of itself, the progressive neurodegeneration that is characteristic of PD can often cause secondary effects that lead to death.
The exact cause of PD is still a mystery, but researchers believe that both genetics and the environment are likely to play a part. Importantly though, all PD patients show a loss of dopaminergic neurons in the brain and increased levels of a protein called ?-synuclein, which accumulates in Lewy bodies. Lewy bodies are a pathological feature of both familial and sporadic forms of the disease, as well as some types of dementia.
In the study published this month in Scientific Reports, the team led by researchers from Osaka University’s Graduate School of Medicine focused on ?-synuclein as a target for a novel PD treatment.
“Although there are drugs that treat the symptoms associated with PD, there is no fundamental treatment to control the onset and progression of the disease,” explains lead author Takuya Uehara. “Therefore, we looked at ways to prevent the expression of ?-synuclein and effectively eliminate the physiological cause of PD.”
To do this, the researchers designed short fragments of DNA that are mirror images of sections of the ?-synuclein gene product. The constructs were stabilized by the addition of amido-bridging. The resulting fragments, called amido-bridged nucleic acid-modified antisense oligonucleotides (ASOs), bind to their matching mRNA sequence, preventing it from being translated into protein. After screening 50 different ASOs, the researchers settled on a 15-nucleotide sequence that decreased ?-synuclein mRNA levels by 81%.
“When we tested the ASO in a mouse model of PD, we found that it was delivered to the brain without the need for chemical carriers,” says co-lead author Chi-Jing Choong. “Further testing showed that the ASO effectively decreased ?-synuclein production in the mice and significantly reduced the severity of disease symptoms within 27 days of administration.”
Explains senior author of the study Hideki Mochizuki, “Our results showed that gene therapy using ?-synuclein-targeting ASOs is a promising strategy for the control and prevention of PD. We expect that in the future, this method will be used to not only successfully treat PD, but also dementia caused by ?-synuclein accumulation.”
Learn more: Stopping Parkinson’s disease before it starts
The Latest on: Parkinson’s disease
via Google News
The Latest on: Parkinson’s disease
- The impact of levodopa therapy-induced complications on quality of life in Parkinson’s disease patients in Singaporeon June 25, 2019 at 9:21 pm
The objective of this study was to investigate the impact of levodopa therapy-induced complications on the quality of life (QoL) of Parkinson’s disease (PD) patients in Singapore over a 1-year ... […]
- Parkinson’s survivor Barry Roberson makes dollhouses for children with cancer and friends in needon June 25, 2019 at 10:40 am
Barry Roberson has Parkinson’s disease and doctors told him he would not live this long but he found therapy and rehabilitation by building dollhouses, which he gives to children with cancer and other ... […]
- Predicting Parkinson's; Dementia and Cancer; Precision Cognitive Agingon June 25, 2019 at 8:40 am
Cancer patients showed better memory function and slower memory decline than similarly aged people who remained cancer-free. (JAMA Network Open) ... […]
- New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partnerson June 25, 2019 at 7:40 am
- "Parkinson's IQ + You" events are designed to empower people with Parkinson's and care partners to manage the disease, learn about research participation and connect with local resources - This ... […]
- Parkinsons Disease Drugs Market Outlook By Size, Share, Future Growth And Forecast From 2016-2022on June 25, 2019 at 5:22 am
Jun 25, 2019 (AmericanNewsHour via COMTEX) -- Introduction Parkinson’s disease is a neurodegenerative disorder which affects the dopamine-producing neurons in a specific area of the brain called ... […]
- Intec Pharma's Accordion Pill for Parkinson's shows positive action in mid-stage studyon June 25, 2019 at 4:43 am
Results from an open-label two-way crossover Phase 2 clinical trial evaluating Intec Pharma's (NASDAQ:NTEC) Accordion Pill - Carbidopa/Levodopa (AP-CD/LD) in Parkinson's disease (PD) patients ... […]
- C4X Discovery and PhoreMost collaboration to accelerate Parkinson’s Disease drug discovery pipelineon June 25, 2019 at 12:00 am
C4X Discovery and PhoreMost collaboration to accelerate Parkinson's Disease drug discovery pipeline C4X Discovery Holdings plc ("C4XD", "C4X Discovery" or the "Company") C4X Discovery and PhoreMost ... […]
- Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membraneson June 24, 2019 at 8:21 am
Parkinson’s disease, the most common age-related movement disorder, is a progressive neurodegenerative disease with unclear etiology. Key neuropathological hallmarks are Lewy bodies and Lewy neurites: ... […]
- New brain imaging study reveals signs of Parkinson’s decades before symptoms appearon June 23, 2019 at 8:43 pm
A new study from King's College London upends conventional thinking about the origins of Parkinson's disease in the brain. The research reveals distinct changes in the brain's serotonin system can ... […]
- Punch Out Parkinson's raises money through golf outing, rock 'n' roll concerton June 23, 2019 at 3:52 pm
People gathered today at the Pleasant View Golf Course to raise funds for Punch Out Parkinson's, an organization donating money to prevent Parkinson's disease. Evan Riley is the founder and organizer ... […]
via Bing News